NCT01496898

Brief Summary

The goal of this study is to examine changes in the bacterial ecology and inflammatory markers of the female genital tract with levonorgestrel intrauterine device placement. The specific research objectives of this project include:

  1. 1.Characterization of vaginal, cervical and uterine bacterial species and communities prior to and after LNG IUD placement using bacterial DNA microarray analysis. Samples will be collected up to 1 week before and 2 months after IUD insertion.
  2. 2.Characterization of vaginal, cervical and uterine inflammatory cytokine milieu prior to and after LNG IUD placement using human RNA microarray analysis. Samples will be analyzed from up to one day before and three weeks after IUD insertion.
  3. 3.Establish a tissue bank of vaginal, cervical and uterine specimens for future research.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
13

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2011

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2011

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

August 21, 2011

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2011

Completed
20 days until next milestone

First Posted

Study publicly available on registry

December 21, 2011

Completed
1.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2013

Completed
Last Updated

January 13, 2016

Status Verified

January 1, 2016

Enrollment Period

11 months

First QC Date

August 21, 2011

Last Update Submit

January 11, 2016

Conditions

Keywords

MicrofloraVaginalCervicalUterineInflammationCytokineIntrauterine DeviceLevonorgestrel

Outcome Measures

Primary Outcomes (1)

  • Changes in vaginal, cervical and uterine bacterial species with levonorgestrel intrauterine device placement

    Characterization of vaginal, cervical and uterine bacterial species and communities prior to and after LNG IUD placement using bacterial DNA microarray analysis

    1 week prior to IUD insertion to 2 months after IUD insertion

Secondary Outcomes (1)

  • Inflammatory cytokine changes with levonorgestrel intrauterine device placement

    1 day prior to IUD insertion to 3 weeks after IUD insertion

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Caucasian woman aged 18 to 45 seeking intrauterine contraception meeting inclusion criteria.

You may qualify if:

  • Not currently pregnant
  • No use of hormonal birth control for at least three months prior to enrollment
  • Desiring levonorgestrel IUD for birth control
  • Greater than 6 months postpartum
  • Greater than 6 weeks after miscarriage
  • No antibiotic use in the past 6 weeks

You may not qualify if:

  • Uterine Abnormalities
  • Current use of hormonal contraceptives or use less than 3 months ago
  • Unexplained vaginal bleeding
  • Irregular menses
  • Cervical dysplasia
  • Cervical or vaginal infection in the last 6 weeks
  • Douching within the week prior to sample collection
  • Use of vaginal lubricants within the week prior to sample collection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Utah Hospital

Salt Lake City, Utah, 84132, United States

Location

Related Publications (1)

  • Jacobson JC, Turok DK, Dermish AI, Nygaard IE, Settles ML. Vaginal microbiome changes with levonorgestrel intrauterine system placement. Contraception. 2014 Aug;90(2):130-5. doi: 10.1016/j.contraception.2014.04.006. Epub 2014 Apr 21.

Biospecimen

Retention: SAMPLES WITH DNA

A total of 648 samples will be collected from 12 participants for bacterial species and human cytokine analysis in 9 collection visits. Specimens will be collected up to one week prior to IUD insertion and two months after IUD insertion. Vaginal and cervical specimens will be collected using FLOQSwabs® (Copan) to maximize bacterial DNA sample collection. Uterine samples will be collected by uterine irrigation with sterile saline using an embryo replacement catheter.

MeSH Terms

Conditions

Inflammation

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Janet C Jacobson, MD

    University of Utah

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
ECOLOGIC OR COMMUNITY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 21, 2011

First Posted

December 21, 2011

Study Start

January 1, 2011

Primary Completion

December 1, 2011

Study Completion

July 1, 2013

Last Updated

January 13, 2016

Record last verified: 2016-01

Locations